• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Galenea

edit

Galenea Corp., a biopharmaceutical company, engages in developing therapeutics for central nervous system (CNS) diseases. The company focuses on psychiatric disorders, schizophrenia and calcineurin, and obesity and 5-HT2C agonists. Its products include in vitro and in vivo synaptic functional screening and brain slice electrophysiology assays, which include techniques for recording disease-relevant neuronal activity in the prefrontal cortex to measure the effects of drug candidates in animals performing critical memory or cognition-dependent tasks. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Recent Milestones

edit

• 
  Galenea received $3M in Grant funding. (9/6/12)
  Posted 9/7/12 at 7:34pm via yahoo.com
• 
  Galenea received $6M in Venture Round funding. (4/26/12)
  Posted 4/26/12 at 7:08pm via finsmes.com
• 
  Galenea received $4.5M in Grant funding. (10/14/10)
  Posted 7/27/11 at 7:32pm via galenea.com
• 
  Galenea added Mark B. Benjamin as President & CEO.
  Posted 7/27/11 at 7:32pm
• 
  Galenea added David Neafus as CFO.
  Posted 7/27/11 at 7:32pm

Videos

Screenshots

edit

Sources

1. Galenea Awarded $4.5 Million Grant for Advancement of Innovative Synaptic Transmission Screen (galenea.com) [edit]
2. Galenea Receives $6M Equity Investment from The Stanley Medical Research Institute (finsmes.com) [edit]
3. Galenea Awarded $3 Million NIH Grant to Develop Translational EEG Biomarkers for Schizophrenia (in.finance.yahoo.com) [edit]